Delving into the Latest Updates on IQVIA RDS Pty Ltd. with Synapse

概览

关联

9

项与 IQVIA RDS Pty Ltd. 相关的临床试验

ACTRN12622001550796 / Active, not recruiting临床1期

A Randomized, Double-blind, Placebo-controlled, Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABBV-CLS-628 in Healthy Adult Volunteers

开始日期2023-05-03

申办/合作机构

Calico LLC

[+1]

NCT05782179 / Completed临床1期

A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of Group B Streptococcus Vaccine (GBS NN/NN2 With Alhydrogel®) in Elderly Participants Aged 55 to 75

The study is a randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and immunogenicity of three doses of GBS NN/NN2 with Alhydrogel® (Recombinant protein vaccine against Group B Streptococcus) in elderly participants aged 55 to 75.Participants will be followed up to 6 months after last vaccination.

开始日期2023-03-01

申办/合作机构

Minervax ApS

[+1]

NCT05560646 / Recruiting临床2期

A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age with Moderate to Severe Endometriosis-related Pain

The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.

开始日期2022-10-25

申办/合作机构